Carcinomatous meningitis (CM) is clinically less common than brain metastasis or spinal cord compression, having dire consequences for both the quality of life and the overall survival of patients with solid tumors. It occurs in about 5% of all adult cancer patients, but autopsies may double this number. If leukemia and lymphoma are excluded, most cases are due to breast cancer, lung cancer and melanoma. In this report, we describe a 49-year-old male patient with metastatic pancreatic adenocarcinoma who developed carcinomatous meningitis. To our knowledge, this is only the second case of carcinomatous meningitis secondary to a pancreatic carcinoma described so far.
Introduction
Most patients with metastatic pancreatic adenocarcinoma have obvious metastases or locally advanced disease at the time of diagnosis presentation. Although patients may experience meaningful palliation from chemotherapy, the median survival varies from a few months up to about a year, the variation probably reflecting differences in patient selection [1] . Carcinomatous meningitis (CM) secondary to primary tumors in the gastro-intestinal tract is clinically infrequent [2] . We describe the development of CM in a patient with metastatic pancreatic adenocarcinoma.
Clinical case
A 49-year-old man presented with a three-month history of fatigue and a weight loss of six kg. The physical examination was unremarkable. A computed tomography (CT) scan of the abdomen and thorax displayed a pancreatic nodule of 3 cm and multiple lytic rib lesions. The histological examination of a CTscan guided biopsy of the pancreatic nodule was consistent with a primary adenocarcinoma of the pancreas. The levels of the carcinoembrionic antigen (CEA) and prostatic specific antigen (PSA) were within the normal ranges. The patient entered a phase II protocol of the SOAD (South American Office for Anticancer Drug Development) Foundation, which involved continuous 21-day infusion of topotecan 0.7 mg/m 2 /day, every 28 days [3] . He also received 90 mg i.v. of pamidronate every three weeks, and codeine and paracetamol as pain medications. After two cycles of chemotherapy, the patient gained 4 kg, improved his performance status (1 -> 0) and achieved excellent pain control. The abdominal CTscan demonstrated that the pancreatic nodule was unchanged. After the third cycle of topotecan, a painful and hard left supraclavicular nodule of 3 cm appeared. No biopsy was done at this time. The patient received 30 Gy of radiotherapy for two weeks, achieving a complete clinical regression of the supraclavicular nodule. Gemcitabine was started at the dose of 1000 mg/m 2 /week for three weeks, every 28 days. One month later, the patient complained of headache and vomiting. A cerebral CT scan showed no abnormalities, but the cerebral spinal fluid (CSF) examination demonstrated 31 cells/mm 3 , with 75% of neoplastic cells consistent with adenocarcinoma, 15% of neutrophils, 6% of eosinophils and 4% of lymphocytes. The protein level was 47 mg/d (N 20-45) and the glucose level was 62 mg/dl.
The patient was treated three times a week with intrathecal (IT) chemotherapy, consisting of methotrexate 15 mg + cytarabine 50 mg + thiothepa 10 mg. Leucovorin rescue was given 24 hours after IT methotrexate, in doses of 15 mg p.o., every six hours for four doses. After the fifth intrathecal treatment the patient had no complaints of headache. The CSF examination demonstrated 2-cells/mtn 3 (lymphocytes) with no visible neoplastic cells. Unfortunately, the patient developed urinary retention and paraplegia, with no signs of compressive epidural metastasis on the dorso-lumbar CT scan and died six weeks later of progressive systemic disease. No autopsy was performed.
Discussion
CM occurs when a tumor spreads to the leptomeninges that surround the brain and spinal cord. Clinical suspicion of CM is based on findings of widely separated cranial nerve and spinal root symptoms, headaches and mental changes. Certain symptoms and signs should lead the physician to suspect CM. These include: headache and vomiting in the absence of any evidence of cerebral metastasis provided by CT or magnetic resonance imaging (MRI) cranial nerve palsies especially diplopia, neck pain in the absence of bone metastasis of the cervical spine, unexplained constipation, impotence, urinary retention or incontinence, and cognitive abnormalities. Interestingly, clinical signs of meningeal irritation are not frequently observed in the initial examination [4] [5] [6] .
The gold standard for diagnosing CM is cytological confirmation of malignant cells in the CSF. Most series report the detection of cancer cells at the first lumbar puncture (LP) in about 70% of cases and in nearly all cases after three LPs [7, 8] . It is uncommon that a patient with CM has a totally negative liquor examination (normal cytology, opening pressure, glucose and protein levels) [7, 9] . When the CSF cytology is negative, tumor markers may help to confirm the diagnosis of CM [10] .
A CTor MRI scan may show contrast enhancement in the basilar cisterns, cortical convexities or the leptomeninges. These findings are not specific and caution must be exercised in cases of negative CSF cytology or poorly defined symptoms. A spinal CT or RMI scan may also suggest the diagnosis by demonstrating small tumor nodules on multiple roots [11, 12] .
Without treatment, CM secondary to solid tumors causes a relentless progression of neurological deficits, culminating in death. Depending on the selection criteria chosen in different studies, patients have a median survival of four to six weeks if left untreated and two to three months with therapy [13] . Some patients may have a prolonged survival, with nearly 10% surviving for one year. This is especially true for breast cancer patients but much less so for patients with lung carcinomas or melanomas [14] . The brain is the most common site to which Radiation therapy (RT) is administered, usually at a dose of 3000 cGy given over 10 fractions, although the cauda equine is also a common site of symptoms requiring RT [6] . If symptomatic hydrocephalus is present, the placement of a ventriculoperitoneal shunt should be considered.
There are a limited number of chemotherapeutic agents that have been tested intrathecally on humans. The most commonly used chemotherapy agents administered by the IT route are methotrexate (MTX), cytarabine and thiothepa.
Thiothepa is used less commonly than the MTX and cytarabine because of its rapid transport out of the subarachnoid space. An Eastern Cooperative Oncology Group study that compared thiothepa to MTX, in patients with previously untreated neoplastic meningitis, found no differences in terms of overall survival or reversion of neurological deficits [15] .
Cytarabine is active against leptomeningeal leukemia and lymphoma. It may also be active against solid tumors normally unresponsive to this agent administered via endovenous route [5] . Recently, a slow-release formulation of cytarabine (DepoCyt) has been developed. In a comparison with the administering of IT MTX to patients with CM from solid tumors, IT DepoCyt led to a greater median time to neurological progression and longer neoplastic meningitis-specific survival. There was however no difference in overall survival [16] .
Due to its activity against breast carcinoma, leukemia and lymphoma, MTX is the most commonly used intrathecal chemotherapeutic agent for the treatment of CM. One study demonstrated that equal results with less toxicity could be achieved by using IT MTX plus RT rather than multiagent intrathecal chemotherapy [17] . There seems to be no advantage in adding cytarabine and dexametasone to the classical schedule of intrathecal MTX [18] . After ITadministration, substantial levels of MTX appear in the serum for prolonged periods of time and may cause mucositis and myelossupression, even if leucovorin rescue is used [5] . At least 35 cases of subacute myeloencephalopathy, with transient or permanent paraplegia/quadriplegia after IT chemotherapy involving methotrexate, cytarabine and thiothepa (alone or in any combination), have been described [19] . In these cases, extensive necrosis of the spinal cord is found at autopsy.
Conclusion
CM of the gastro-intestinal tract origin is clinically infrequent and to our knowledge, there is only one previous report of meningeal carcinomatosis due to pancreatic adenocarcinoma [20] . We speculate that the period of tumor stabilization achieved in this patient allowed the clinical expression of the meningeal component of his disease. The treatment with IT chemotherapy offered good palliative control of the patient's symptoms, namely headache. The reason for the development of paraplegy is unknown. It may have been related to the progressive nature of the neoplasm or to the IT chemotherapy treatment received.
CM remains a common problem encountered in every-day practice. Early diagnosis and good clinical determination of the patients who will derive benefit from treatment are two of the challenges faced by oncologists confronting the disease. New approaches to its prevention and treatment are clearly needed.
